Smaller acquisitions and disciplined pricing are proving to be big benefits to a wider number of companies ...

Vertex Pharmaceuticals' business will suffer if other drugmakers launch competing cystic fibrosis drugs. Despite this threat, ...

The threat of new tariffs on drugmakers has set off a debate within the biotech industry over whether to cut voluntary ...

Companies have long lamented Europe's fragmented capital markets, single-market adoption on pricing and clinical trials, and ...

In this week’s edition of InnovationRx, we look at the first robotic cataract surgeries in humans, the underbelly of ...

Pete Pharma, a pharmaceutical innovation and IP development company focused on modernizing dosage forms through advanced 3D ...

Gilead to Buy Ouro Medicines for $2.2 Billion. Why the Deal Is Key to Future Stock Gains. Gilead plans to develop Ouro’s lead drug candidate, gamgertamig, alongside a Belgian pharma company. Nvidia ...

China’s biotechs are faster and have lower costs, and its drug research threatens to soon overtake the West’s ...

When MEI Pharma announced it was considering its “strategic alternatives” in the wake of a failed merger last year, the options seemed pretty mundane. But, rather than winding down the company as the ...

In today's Pharmaceutical Executive Daily, Eli Lilly releases updated safety data for its oral obesity pill Foundayo in ...

West Pharmaceutical (WST) possesses the right combination of the two key ingredients for a likely earnings beat in its ...

As President Trump’s war in Iran rages on, it’s posing a growing threat to the pharmaceutical supply chain and risks spiking ...